$GILD news
The latest GILD stock news: headlines, filings, AI summaries and sentiment for $GILD, updated around the clock.
- GILEAD SCIENCES, INC. - 4 Filing
- Compugen Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- GILEAD SCIENCES, INC. - 4 Filing
- Vir Bio Reports Q3 2026 Financial Results and Gilead Collaboration Details
- Gilead Sciences Maintains 11-Year Dividend Growth Streak Supported by HIV and Oncology Revenue
- Major US Indexes and Biotech Sector Rally Following Election and Strong Earnings
- Dr. Reddy's Laboratories Receives FDA Tentative Approval for Generic Version of Gilead's Yeztugo
- GILEAD SCIENCES, INC. - 4 Filing
- Gilead Sciences Announces Quarterly Dividend of $0.82 Per Share
- Gilead Sciences Shows Strong Growth Driven by HIV and Liver Disease Portfolios
- Gilead Sciences Reports Strong Q3 2026 Results Driven by HIV and Oncology Growth
- GILEAD SCIENCES, INC. - 10-Q Filing
- Gilead Sciences Reports Strong Q3 Growth and Raises 2026 Base Business Guidance
- Gilead Sciences Widens 2026 Non-GAAP Loss Forecast Despite Q3 Earnings Beat
- Kymera Therapeutics Reports Q3 2026 Results and Positive Phase I Data for KT-579
- GILEAD SCIENCES, INC. - 8-K Filing
- Major Corporate Earnings Scheduled After Market Close on Thursday
- Gilead Sciences Receives Multiple FDA Approvals and Label Expansions
- Vir Biotechnology Licenses Technology to Gilead for Up to $1.9 Billion
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- Lakefront Biotherapeutics to Begin Registrational Trials for Gamgertamig by 2027
- Morgan Stanley Maintains Overweight Rating on Gilead Sciences Amid Strong Performance in HIV Prevention
- Morgan Stanley Maintains Positive Outlook on Gilead Sciences, Highlighting HIV Prevention Franchise
- Gilead Expands HIV Drug Access to Latin America via PAHO Agreement
- Class Action Lawsuit Filed Against iTonic Holdings Ltd Over Alleged Securities Fraud
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- Lilly Holds Up Amid Drug Stock Declines; Boeing Reports Mixed Delivery Results
- GILEAD SCIENCES, INC. - 4 Filing
- Gilead Sciences Shares Rise on Strong HIV Drug Portfolio Performance
- U.S. FDA Approves Gilead's Once-Daily HIV Pill Bixlenvo
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing
- California Supreme Court Rules in Favor of Gilead Sciences on 'Duty to Innovate' Case
- Atea Pharmaceuticals Reports Positive Phase 3 Trial Results for Hepatitis C Treatment
- Germany's Deep Tech Sector Drives Growth in VC Funding
- EU Drug Regulator Approves New Medicines Including Products From J&J and Gilead
- Gilead Sciences to Report Q2 Earnings Amid Analyst Expectations of Loss
- GILEAD SCIENCES, INC. - 4 Filing
- GILEAD SCIENCES, INC. - 4 Filing